Which baseline and follow‑up laboratory tests should be ordered after starting perindopril 4 mg and amlodipine 5 mg daily in an adult with severe hypertension?

Laboratory Monitoring After Starting Perindopril 4 mg and Amlodipine 5 mg

Check serum electrolytes (sodium, potassium) and renal function (creatinine, eGFR) 2 to 4 weeks after initiating therapy with perindopril and amlodipine. 1, 2

Baseline Laboratory Tests (Before or At Initiation)

Before starting this combination, the following baseline labs should be obtained:

• Serum creatinine and eGFR to assess baseline kidney function 3
• Serum potassium to establish baseline before ACE inhibitor therapy 4, 2
• Serum sodium as thiazide diuretics (if added later) can cause hyponatremia 4
• Urine albumin-to-creatinine ratio (ACR) to screen for kidney disease 3
• Fasting lipid panel and glucose to assess cardiovascular risk factors 3

Follow-Up Laboratory Tests After Initiation

At 2-4 Weeks Post-Initiation

The most critical monitoring window is 2 to 4 weeks after starting therapy, when you must check: 1, 2

• Serum potassium: ACE inhibitors like perindopril increase risk of hyperkalemia, especially in patients with chronic kidney disease or those on potassium supplements 4, 2, 4
• Serum creatinine and eGFR: To detect acute changes in renal function, particularly important as ACE inhibitors can cause acute renal failure in patients with bilateral renal artery stenosis 4, 2
• Serum sodium: To establish a new baseline after medication changes 4

Ongoing Monitoring Schedule

After the initial 2-4 week check:

• Repeat BP measurement at 1 month to assess treatment response in severe hypertension 4, 2, 1
• Annual monitoring of creatinine, eGFR, and urine ACR if moderate-to-severe CKD is diagnosed 3
• Periodic potassium checks especially if doses are uptitrated or additional medications are added 4, 2

High-Risk Populations Requiring More Intensive Monitoring

Monitor more frequently (every 1-2 weeks initially) in patients with:

• Chronic kidney disease (CKD): Higher risk of hyperkalemia and acute kidney injury with ACE inhibitors 4, 2, 5
• Concurrent potassium-sparing medications: Including spironolactone, amiloride, or potassium supplements 4, 2
• Diabetes mellitus: Already at increased cardiovascular risk requiring closer monitoring 3
• Bilateral renal artery stenosis: Risk of acute renal failure with ACE inhibitors 4, 2

Common Pitfalls to Avoid

• Do not skip the 2-4 week renal/electrolyte check: This is when ACE inhibitor-related complications typically manifest 1, 2
• Do not combine perindopril with ARBs or renin inhibitors: Dual RAS blockade increases hyperkalemia and acute kidney injury risk without cardiovascular benefit 4, 5
• Do not ignore symptoms of hyperkalemia: Muscle weakness, palpitations, or ECG changes warrant immediate potassium measurement 4, 2
• Monitor for orthostatic hypotension in older patients or those with postural symptoms, though this is clinical rather than laboratory monitoring 2, 1

Additional Clinical Monitoring (Non-Laboratory)

While not laboratory tests, also monitor:

• Blood pressure response at 1 month with office, home, or ambulatory BP monitoring 4, 2, 1
• Medication adherence before considering dose escalation 6
• Peripheral edema as a dose-dependent side effect of amlodipine 6